Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs

Autor:	Ariadna Tibau, A. Ocana Fernandez, C. Molto Valiente, L. Del Carpio Huerta, Arnoud J. Templeton, Christopher M. Booth, Eitan Amir, Agust Barnadas, J.C. Del Paggio
Rok vydání:	2017
Předmět:	medicine.medical_specialty business.industry Fda approval Alternative medicine Hematology Pharmacology Orphan drug Food and drug administration Clinical trial Clinical research Oncology Medicine business Intensive care medicine
Zdroj:	Annals of Oncology. 28:v642
ISSN:	0923-7534
DOI:	10.1093/annonc/mdx440.063
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::586f4a1e6530bfcfc561e8fe63392c18 https://doi.org/10.1093/annonc/mdx440.063 Zobrazit plný text záznamu